Immunitybio, Inc. 8-K Filing
Ticker: IBRX · Form: 8-K · Filed: Nov 5, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Immunitybio, Inc. (ticker: IBRX) to the SEC on Nov 5, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Select).
How long is this filing?
Immunitybio, Inc.'s 8-K filing is 2 pages with approximately 575 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-11-04 21:48:22
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Select
Filing Documents
- ibrx-20251104.htm (8-K) — 30KB
- ibrx-2025114x8kexhibit991.htm (EX-99.1) — 128KB
- image_0.jpg (GRAPHIC) — 2KB
- 0001326110-25-000138.txt ( ) — 290KB
- ibrx-20251104.xsd (EX-101.SCH) — 2KB
- ibrx-20251104_lab.xml (EX-101.LAB) — 21KB
- ibrx-20251104_pre.xml (EX-101.PRE) — 12KB
- ibrx-20251104_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 4, 2025, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the third quarter and nine months ended September 30, 2025, and its financial position as of September 30, 2025. The full text of the Company's press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filings of the Company made under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing. Section 9 – Financial Statements and Exhibits.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description of Exhibit 99.1** Press release dated November 4 , 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). _______________ ** Furnished herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: November 4, 2025 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer